STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

Back to Search
Print
Bookmark Trial

NCT04635631

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Jilin Cancer Hospital
Changchun, Jilin, 130000, China
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histological or cytological diagnosis of locally advanced or metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.

- ECOG Performance Status 0 or 1.

- Adequate Bone Marrow, Renal and Liver Function.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Participants with brain metastases.


- Current or anticipated use of P gp inhibitor and/or inducer within 7 days prior to
study intervention from lead-in to end of Cycle 1; concomitant use of potent P gp
inhibitor after Cycle 1 until the end of treatment.


- Prior treatment with a PARP inhibitor.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

NeoplasmsSTUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
NCT04635631
  1. Changchun, Jilin
  2. Beijing,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
NeoplasmsBRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)
NCT04607421
  1. Basking Ridge, New Jersey
  2. Middletown, New Jersey
  3. Montvale, New Jersey
  4. Commack, New York
  5. Harrison, New York
  6. New York, New York
  7. New York, New York
  8. Uniondale, New York
  9. Duarte, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. Los Angeles, California
  13. Los Angeles, California
  14. Los Angeles, California
  15. Pasadena, California
  16. Creve Coeur, Missouri
  17. Florissant, Missouri
  18. Saint Louis, Missouri
  19. Saint Louis, Missouri
  20. Saint Louis, Missouri
  21. Saint Louis, Missouri
  22. Saint Peters, Missouri
  23. Clarksville, Tennessee
  24. Franklin, Tennessee
  25. Gallatin, Tennessee
  26. Germantown, Tennessee
  27. Hendersonville, Tennessee
  28. Hermitage, Tennessee
  29. La Vergne, Tennessee
  30. Lebanon, Tennessee
  31. Memphis, Tennessee
  32. Murfreesboro, Tennessee
  33. Nashville, Tennessee
  34. Nashville, Tennessee
  35. Nashville, Tennessee
  36. Nashville, Tennessee
  37. Nashville, Tennessee
  38. Nashville, Tennessee
  39. Nashville, Tennessee
  40. Nashville, Tennessee
  41. Smyrna, Tennessee
  42. Houston, Texas
  43. Houston, Texas
  44. Herston, Queensland
  45. Adelaide, South Australia
  46. Clayton, Victoria
  47. Melbourne, Victoria
  48. Kashiwa, Chiba
  49. Seoul,
  50. Seoul,
  51. Utrecht,
  52. Barcelona,
  53. Madrid,
  54. Madrid,
  55. Valencia,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
NeoplasmsPharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies
NCT00859118
  1. Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
NeoplasmsSafety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors
NCT00095160
  1. Minneapolis, Minnesota
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
Official Title  ICMJE AN OPEN-LABEL, SINGLE-ARM, PHASE 1 STUDY OF PHARMACOKINETICS, SAFETY AND ANTI-TUMOR ACTIVITY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
Brief Summary A phase1 study to evaluate the PK (single dose and multiple doses) and safety of talazoparib 1 mg Once Daily in Chinese adult participants with advanced solid tumors. A maximum of approximately 15 participants will be enrolled such that approximately 12 evaluable participants complete the study.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Neoplasms
Intervention  ICMJE Drug: talazoparib
Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days.
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: November 13, 2020)		15
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE April 2, 2022
Estimated Primary Completion Date November 12, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histological or cytological diagnosis of locally advanced or metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
  • ECOG Performance Status 0 or 1.
  • Adequate Bone Marrow, Renal and Liver Function.

Exclusion Criteria:

  • Participants with brain metastases.
  • Current or anticipated use of P gp inhibitor and/or inducer within 7 days prior to study intervention from lead-in to end of Cycle 1; concomitant use of potent P gp inhibitor after Cycle 1 until the end of treatment.
  • Prior treatment with a PARP inhibitor.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04635631
Other Study ID Numbers  ICMJE C3441049
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date December 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP